Related Experiment Videos
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
G Zeng1, C E Touloukian, X Wang
1Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
In previous studies, the shared cancer-testis Ag, NY-ESO-1, was demonstrated to be recognized by both Abs and CD8+ T cells. Gene expression of NY-ESO-1 was detected in many tumor types, including melanoma, breast, and lung cancers, but was not found in normal tissues, with the exception of testis. In this study, we describe the identification of MHC class II-restricted T cell epitopes from NY-ESO-1. Candidate CD4+ T cell peptides were first identified using HLA-DR4 transgenic mice immunized with the NY-ESO-1 protein. NY-ESO-1-specific CD4+ T cells were then generated from PBMC of a patient with melanoma stimulated with the candidate peptides in vitro. These CD4+ T cells recognized NY-ESO-1 peptides or protein pulsed on HLA-DR4+ EBV B cells, and also recognized tumor cells expressing HLA-DR4 and NY-ESO-1. A 10-mer peptide (VLLKEFTVSG) was recognized by CD4+ T cells. These studies provide new opportunities for developing more effective vaccine strategies by using tumor-specific CD4+ T cells. This approach may be applicable to the identification of CD4+ T cell epitopes from many known tumor Ags recognized by CD8+ T cells.
Insights
Researchers identified new CD4+ T cell epitopes from the NY-ESO-1 tumor antigen. These findings offer novel strategies for developing effective cancer vaccines targeting tumor-specific T cells.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- NY-ESO-1 is a shared cancer-testis antigen found in various cancers but not normal tissues (except testis).
- NY-ESO-1 is recognized by antibodies and CD8+ T cells, indicating its potential as a cancer immunotherapeutic target.
Purpose of the Study:
- To identify MHC class II-restricted T cell epitopes from the NY-ESO-1 antigen.
- To explore the potential of CD4+ T cells targeting NY-ESO-1 for cancer vaccine development.
Main Methods:
- Utilized HLA-DR4 transgenic mice immunized with NY-ESO-1 protein to identify candidate CD4+ T cell peptides.
- Generated NY-ESO-1-specific CD4+ T cells from melanoma patient PBMCs stimulated with candidate peptides in vitro.
- Assessed recognition of NY-ESO-1 peptides/protein by CD4+ T cells pulsed on HLA-DR4+ EBV B cells and tumor cells.
Main Results:
- Identified a specific 10-mer peptide (VLLKEFTVSG) recognized by CD4+ T cells.
- Demonstrated that generated CD4+ T cells recognize NY-ESO-1 on antigen-presenting cells and tumor cells expressing HLA-DR4 and NY-ESO-1.
Conclusions:
- The identification of MHC class II-restricted CD4+ T cell epitopes from NY-ESO-1 opens new avenues for cancer vaccine strategies.
- This approach can be extended to discover CD4+ T cell epitopes from other tumor antigens recognized by CD8+ T cells, enhancing immunotherapy development.